The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Genetic targeting in sickle cell disease
Erica Esrick, MD, of Harvard Medical School, Boston, MA, discusses the inital results of the genetic targeting of BCL11A in sickle cell disease using a shRNAmiR lentiviral vector. This gene therapy showed promising results, as presented here at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
